Biotech has been one of the worst-performing industry groups this cycle. Investors have got used to it as these stocks have been dead money for much of the past decade.
Today's trade is in a big cap leader that has been in a little drawdown off highs over the past couple of weeks. This, coupled with earnings coming up next week has options premiums juiced.
It doesn’t matter if it’s a new trading strategy, a new instrument—like moving from stocks to options or options to futures—or a new way of doing research… newness brings discomfort. It’s awkward. You don’t know what...
I've been loving how this boring utility space name has been consolidating near all-time highs since February. Most people have probably been bored to tears if they've been in it. Longs are comfortable, shorts are asleep. Great.
